PCVX: Vaxcyte Inc Company Value to Net Income

Corporate emblem and logo of Vaxcyte Inc (PCVX)

Vaxcyte, Inc. (PCVX) is challenging industry leaders by developing potent vaccines against bacterial threats. The temporary trajectory on the GURU.Markets chart regarding the company's P/E ratio reflects the dynamics of a biotech startup focused on the B2G sector. However, geopolitical risks are hindering drug registration and logistics. The value of -9.40 captures the current indicator level, confirming the business's financial pulse.

Vaxcyte Inc (PCVX) Price to Earnings Ratio: for the period 07/04/2022 - 11/12/2026

Comprehensive metric breakdowns and analytics for Vaxcyte Corp (PCVX)

- price and consensus price forecast:
Stock Price vaxcyte.com|PCVX - Consensus Target
- market capitalization information:
Market Value Vaxcyte, Inc.|PCVX - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Share Vaxcyte|PCVX - Company Book Value|Capitalization to Book Value Ratio vaxcyte.com|PCVX - Company Total Assets
- debt and solvency information:
Aggregate Debt to Equity Vaxcyte, Inc.|PCVX - Long-Term Debt to Capital|Current Liabilities to Capital SutroVax|PCVX - Company Aggregate Debts|Debt to Book Value Vaxcyte, Inc.|PCVX - Company Long-Term Liabilities|Amount of Current Liabilities Vaxcyte|Interim Coverage Ratio vaxcyte.com
- earnings and market multiples details:
PCVX - Company Net Income|Expected Net Profit Vaxcyte, Inc.|PCVX - Price to Earnings Ratio|Price to Future Earnings Ratio Vaxcyte Inc|PCVX - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Vaxcyte, Inc.|PCVX - Operating profit before deduction of amortization|Earnings per share for the last twelve months Vaxcyte|PCVX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth vaxcyte.com|PCVX - Net earnings per share growth this year|Projected earnings per share growth rate for next year Vaxcyte, Inc.
Summary company analysis:PCVX vaxcyte.com
Manufactured products of Vaxcyte

Investors are assessing the resilience of Vaxcyte, Inc. (PCVX) through the ratio of the business's market value to its annual net income, which determines the cost of each unit of earnings. By analyzing the P/E fundamental multiple of Vaxcyte, Inc. (PCVX), one can understand how the market currently prices in the potential for explosive growth of innovative pneumococcal vaccines amidst fierce competition with global pharma behemoths.

Competing companies

P/E Multiple summittxinc.com|Price to Earnings Ratio MRNA (Moderna)|TARS (Tarsus Pharmaceuticals Inc) - Company Value to Net Income|P/E Multiple CRMD (CorMedix Corp)|Business Payback Period Seres Therapeutics, Inc (MCRB)|SPRO - Price to Earnings Ratio|SCYX (SCYNEXIS, Inc.) - Price to Earnings Multiple|ANTX: P/E Multiple|Market Cap to Net Income PYPD (PolyPid)|LSB (YS Biopharma) - P/E Multiple|Market Cap to Earnings Iterum Therapeutics, plc ITRM|P/E Multiple PHGE|Price to Earnings Ratio soligenix.com SNGX|60 Degrees Pharmaceuticals, Inc. - Price to Earnings Ratio|Market Price to Net Income Ratio OGEN (oragenics.com)|OpGen Corp - P/E Multiple